MX2012006744A - Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. - Google Patents

Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.

Info

Publication number
MX2012006744A
MX2012006744A MX2012006744A MX2012006744A MX2012006744A MX 2012006744 A MX2012006744 A MX 2012006744A MX 2012006744 A MX2012006744 A MX 2012006744A MX 2012006744 A MX2012006744 A MX 2012006744A MX 2012006744 A MX2012006744 A MX 2012006744A
Authority
MX
Mexico
Prior art keywords
treatment
ppar
combinations
diabetes mellitus
metabolic diseases
Prior art date
Application number
MX2012006744A
Other languages
English (en)
Inventor
Scott D Larsen
Steven P Tanis
Rolf F Kletzien
Gerard R Colca
Original Assignee
Metabolic Solutions Dev Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Solutions Dev Co Llc filed Critical Metabolic Solutions Dev Co Llc
Publication of MX2012006744A publication Critical patent/MX2012006744A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se refiere a análogos de tiazolidinadionas y composiciones farmacéuticas que son útiles para tratar y/o prevenir diabetes mellitus, opcionalmente en combinción con un segundo tratamientol. Adicionalmente, la presente invención también proporciona métodos para inducir la remisión de los síntomas de diabetes mellitus en un paciente que comprende en administrar un análogo de tiazolinidinadionas y un agonista de GLP-1.
MX2012006744A 2009-12-15 2010-12-15 Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. MX2012006744A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28673809P 2009-12-15 2009-12-15
US28676509P 2009-12-15 2009-12-15
US29674810P 2010-01-20 2010-01-20
PCT/US2010/060453 WO2011084456A1 (en) 2009-12-15 2010-12-15 Ppar-sparing thiazolidinediones and combinations for the treatment of diabetes mellitus and other metabolic diseases

Publications (1)

Publication Number Publication Date
MX2012006744A true MX2012006744A (es) 2012-07-30

Family

ID=43707800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006744A MX2012006744A (es) 2009-12-15 2010-12-15 Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.

Country Status (10)

Country Link
US (1) US20120322728A1 (es)
EP (1) EP2512471A1 (es)
JP (1) JP2013514369A (es)
KR (1) KR20120092712A (es)
CN (1) CN102753170A (es)
AU (1) AU2010340058A1 (es)
CA (1) CA2783264A1 (es)
MX (1) MX2012006744A (es)
RU (1) RU2012130011A (es)
WO (1) WO2011084456A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2783468C (en) 2009-12-15 2018-10-09 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinedione salts for the treatment of metabolic diseases
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366691A1 (en) 2012-12-21 2015-07-09 Sanofi Exendin-4 derivatives
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2017070689A2 (en) 2015-10-23 2017-04-27 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
US20210038566A1 (en) 2018-02-08 2021-02-11 Enyo Pharma Use of modulators of neet proteins for the treatment of infection
US11931345B2 (en) * 2018-05-04 2024-03-19 Cirius Therapeutics, Inc. Thiazolidinedione analogs for the treatment of NAFLD and metabolic diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US7230016B2 (en) * 2003-05-13 2007-06-12 Synthon Ip Inc. Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
CN101448500A (zh) * 2006-03-16 2009-06-03 新陈代谢解决方案开发公司 噻唑烷二酮类似物和糖皮质激素激动剂的组合疗法
ES2397944T3 (es) * 2006-03-16 2013-03-12 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona
RU2486179C2 (ru) * 2007-09-14 2013-06-27 МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи Аналоги тиазолидиндиона для лечения диабета и дислипидемии
WO2010105048A1 (en) * 2009-03-12 2010-09-16 Metabolic Solutions Development Company Thiazolidinedione analogues

Also Published As

Publication number Publication date
WO2011084456A9 (en) 2012-06-21
CA2783264A1 (en) 2011-07-14
CN102753170A (zh) 2012-10-24
RU2012130011A (ru) 2014-01-27
EP2512471A1 (en) 2012-10-24
WO2011084456A1 (en) 2011-07-14
JP2013514369A (ja) 2013-04-25
AU2010340058A1 (en) 2012-06-21
US20120322728A1 (en) 2012-12-20
KR20120092712A (ko) 2012-08-21

Similar Documents

Publication Publication Date Title
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
MX2012006734A (es) Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de obesidad y otras enfermedades metabolicas.
PH12018501424B1 (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog
AR081254A1 (es) Composicion farmaceutica que comprende ave0010 e insulina glargina
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
EA201190054A1 (ru) Аналоги глюкагона
EA201190047A1 (ru) Аналоги глюкагона
EA201190048A1 (ru) Аналоги глюкагона
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
WO2008050329A3 (en) Novel sirnas and methods of use thereof
MX2012000488A (es) Terapia de combinacion para el tratamiento de la diabetes.
NZ608829A (en) Pharmaceutical composition comprising an sglt2-inhibitor, methods for treating and uses thereof
WO2008120813A1 (ja) ジペプチジルペプチダーゼ４阻害化合物と甘味料との併用
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
EA200870575A1 (ru) Композиции и способы лечения застойной сердечной недостаточности
MX2013008484A (es) Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2.
WO2012125830A3 (en) Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control
MX2013013307A (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
WO2011112867A8 (en) The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2012063134A3 (en) Cardiac glycoside analogs in combination with emodin for cancer therapy
MX2013008374A (es) Apolipoproteina a-iv como un peptido antidiabetico.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal